Lysophosphatidic Acid in Ovarian Cancer Patients
Sedláková I.1, Vávrová J.2, Tošner J.1, Hanousek L.3
1Gynekologicko-porodnická klinika LF UK a FN Hradec Králové, přednosta doc. MUDr. J. Tošner, CSc. 2Ústav klinické biochemie a diagnostiky FN Hradec Králové, přednosta prof. MUDr. V. Palička, CSc. 3Gynekologicko-porodnické oddělení, Krajská nemocnice Pardubice, primář MUDr. L. Hanousek, CSc. |
|
Summary:
Objective: To compare plasma lysophosphatidic acid (LPA) level in ovarian cancer patients and women
without ovarian pathology.
Design: Prospective study.
Setting: Department of Gynecology and Obstetrics, University Hospital, Hradec Králové.
Methods: The method for LPA level analyze with its specification by capillary electrophoresis using indirect
ultraviolet detection has been implementated. Since the beginning of this project venous blood samples
from 103 patients (60 patients with ovarian cancer, 43 patients without ovarian pathology) have been
obtained.
Results: Plasma LPA levels were elevated in ovarian cancer patients (Σ LPA Med 19.9 μmol/l, Range 4.5
– 42.7 μmol/l). Patients without ovarian pathology (n=35) (Σ LPA Med 2.6 μmol/l, Range 0.9 – 22.9
μmol/l, P<0,001) had statistically significant lower plasma LPA level compared with ovarian cancer patients.
Conclusion: Lysophosphatidic acid appears useful as diagnostic marker of ovarian cancer.
Key words:
ovarian cancer, lysophosphatidic acid, marker
|
